These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21102481)

  • 1. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
    TAN WF; Qiu ZQ; YU Y; RAN RZ; YI B; LAU WY; LIU C; QIU YH; FENG FL; WANG JH; YAN PN; ZHANG BH; WU MC; LUO XJ; JIANG XQ
    Acta Pharmacol Sin; 2010 Dec; 31(12):1643-8. PubMed ID: 21102481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
    BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
    Qu XD; Chen CS; Wang JH; Yan ZP; Chen JM; Gong GQ; Liu QX; Luo JJ; Liu LX; Liu R; Qian S
    BMC Cancer; 2012 Jun; 12():263. PubMed ID: 22721173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
    Dufour JF; Hoppe H; Heim MH; Helbling B; Maurhofer O; Szucs-Farkas Z; Kickuth R; Borner M; Candinas D; Saar B
    Oncologist; 2010; 15(11):1198-204. PubMed ID: 21036880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
    Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
    Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
    Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
    Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
    Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
    Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
    Xu LT; Chen Z; Lin JH; Zhou ZH; Chen H; Meng ZQ; Liu LM
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):703-5. PubMed ID: 21122388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
    Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
    Sieghart W; Pinter M; Reisegger M; Müller C; Ba-Ssalamah A; Lammer J; Peck-Radosavljevic M
    Eur Radiol; 2012 Jun; 22(6):1214-23. PubMed ID: 22215073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
    Pfiffer TE; Seehofer D; Nicolaou A; Neuhaus R; Riess H; Trappe RU
    Tumori; 2011; 97(4):436-41. PubMed ID: 21989430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
    J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
    Zhang K; Sun X; Xie F; Jian W; Li C
    J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
    Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.